Brand name Flovent HFA (fluticasone propionate) and Flovent Diskus will be discontinued at the end of 2023. MassHealth will continue to require prior authorization for the authorized generic of Flovent HFA.
Given this change in product availability, MassHealth will be making coverage updates in the inhaled corticosteroid (ICS) inhaler class as part of the December rollout (effective Dec. 4, 2023).
- Brand Flovent HFA and Flovent Diskus will continue to be covered without prior authorization. Members can fill brand Flovent HFA and Flovent Diskus until the supply runs out. However, not switching members to an alternative prior to the end of the year could result in abrupt interruptions in therapy.
- Generic Flovent HFA will not be preferred and will require prior authorization.
- Approval criteria for generic Flovent HFA will require trial and failure with at least two less costly alternatives.
- Through March 4, 2024, stability on Flovent HFA will be considered a reason for a one-month approval of generic Flovent HFA.
Director, Provider Relations & Communications
Senior Manager, Provider Communications
Joseph O’Riordan, Susan Panos, Stephen Wong,